Cargando…
Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial
BACKGROUND: A previous trial showed that autologous ex‐vivo expanded NK cell (SNK01) treatment combined with pembrolizumab showed better efficacy than pembrolizumab monotherapy in advanced non‐small cell lung cancer (NSCLC). This study was a 2‐year follow‐up of that previous study to determine the l...
Autores principales: | Park, Hyung Jun, Kim, Yong Man, Jung, Jae Seob, Ji, Wonjun, Lee, Jae Cheol, Choi, Chang‐Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284127/ https://www.ncbi.nlm.nih.gov/pubmed/35670036 http://dx.doi.org/10.1111/1759-7714.14523 |
Ejemplares similares
-
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non–Small Cell Lung Cancer
por: Kim, Eo Jin, et al.
Publicado: (2022) -
Validation of the General and Sport Nutrition Knowledge Questionnaire (GeSNK) in Spanish Adolescents
por: Manzano-Felipe, María Ángeles, et al.
Publicado: (2022) -
Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022) -
Validation of a General and Sport Nutrition Knowledge Questionnaire in Adolescents and Young Adults: GeSNK
por: Calella, Patrizia, et al.
Publicado: (2017) -
P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand
por: Hemachandra, A, et al.
Publicado: (2009)